Literature DB >> 7961712

Formation of heterodimers from three neurotrophins, nerve growth factor, neurotrophin-3, and brain-derived neurotrophic factor.

T Arakawa1, M Haniu, L O Narhi, J A Miller, J Talvenheimo, J S Philo, H T Chute, C Matheson, J Carnahan, J C Louis.   

Abstract

Three neurotrophic factors, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and nerve growth factor (NGF) form noncovalent homodimers in solution. Since they are highly homologous proteins, it seemed probable that two monomers of these proteins might associate together to form a heterodimer. This was tested by denaturing the two different proteins together in 6 M guanidine HCl and refolding them in phosphate-buffered saline. When the refolded mixture of BDNF and NT-3 was subjected to Mono S cation exchange chromatography, a new peak was observed eluting between NT-3 and BDNF, which accounted for about 30% of the protein used. This new protein species migrated as a single band upon native gel electrophoresis with mobility between that of the NT-3 homodimer and the BDNF homodimer, indicating that a complex had been formed. Sedimentation equilibrium data show that the dissociation constant of this heterodimer is < 3 x 10(-10) M. The heterodimer was stable upon incubation at 37 degrees C in phosphate-buffered saline over 11 days. Having determined that the heterodimer is highly stable, it was subjected to various biological assays. Autophosphorylation assay using TrkB receptor showed that the heterodimer is indistinguishable from the BDNF or NT-3 homodimer in the ability to induce phosphorylation of the receptor. It was also indistinguishable from the homodimers in the neurotrophic activity using chick dorsal root ganglion explant. In the sympathetic neuron survival assay, the heterodimer behaved more similarly to NT-3, whereas in the dopamine uptake assay, it was intermediate between the two homodimers. In addition, the heterodimer was shown to be retrogradely transported in the dorsal root ganglion neurons. A heterodimer between NGF and BDNF is formed but much less effectively than the NT-3.BDNF heterodimer, and it is not stable even at 4 degrees C. These results indicate that BDNF and NT-3 have an intersubunit contact surface for dimerization resembling each other's but different from the contact surface of NGF.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961712

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity.

Authors:  T Sakane; W M Pardridge
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

2.  The structures of the neurotrophin 4 homodimer and the brain-derived neurotrophic factor/neurotrophin 4 heterodimer reveal a common Trk-binding site.

Authors:  R C Robinson; C Radziejewski; G Spraggon; J Greenwald; M R Kostura; L D Burtnick; D I Stuart; S Choe; E Y Jones
Journal:  Protein Sci       Date:  1999-12       Impact factor: 6.725

3.  Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration.

Authors:  W M Pardridge; D Wu; T Sakane
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

4.  Neurotrophin-3 sorts to the constitutive secretory pathway of hippocampal neurons and is diverted to the regulated secretory pathway by coexpression with brain-derived neurotrophic factor.

Authors:  H F Farhadi; S J Mowla; K Petrecca; S J Morris; N G Seidah; R A Murphy
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

Review 5.  A New Method to Characterize Conformation-Specific Antibody by a Combination of Agarose Native Gel Electrophoresis and Contact Blotting.

Authors:  Teruo Akuta; Toshiaki Maruyama; Chiaki Sakuma; Masataka Nakagawa; Yui Tomioka; Kevin Entzminger; Jonathan K Fleming; Ryo Sato; Takashi Shibata; Yasunori Kurosawa; C J Okumura; Tsutomu Arakawa
Journal:  Antibodies (Basel)       Date:  2022-05-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.